Cancer NetworkOriginal article
<![CDATA[OST-HER2 Yields Significant 3-Year Survival in Pulmonary Osteosarcoma]]>
Phase 2positiveOST-HER2Positive
AI Analysis
Summary
OST-HER2 demonstrated significant 3-year overall survival benefit in a phase 2b trial of fully resected pulmonary metastatic osteosarcoma, with 71.2% OS rates compared to 45.8% in historical controls.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Interim 3-year OS rates of 71.2% with OST-HER2 vs 45.8% in historical controls in phase 2b trial of fully resected pulmonary metastatic osteosarcoma
Importance:6/10
Sentiment:
0.75
oncologyosteosarcomaphase 2bsurvival dataHER2-targeted
Read the original article
Published by Cancer Network on September 9, 2026 4:00 PM